One June 3, a workshop titled “Metabolism in MS and Related Conditions” was presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held June 1-4 in National Harbor, Maryland. One of the speakers was Dr. David Sheikh-Hamad, professor of medicine-nephrology at Baylor College of…
research
A single genetic mutation in a gene called Nr1h3, can cause familial multiple sclerosis (MS), reported scientists from the University of British Columbia and Vancouver Coastal Health. The study, “Nuclear Receptor NR1H3 in Familial Multiple Sclerosis” was published in the journal Neuron. The discovery…
Increasing evidence suggests that our gut microbiome is able to regulate brain processes and trigger neurological disorders, such as multiple sclerosis (MS). Scientists from around the world discussed these themes at the recent Congress of the European Academy of Neurology in Copenhagen, Denmark. “The gut microbiome can influence the central…
Most research in multiple sclerosis (MS) has focused on the impact of the disease on the lower extremities. To balance this, researchers at Mount Sinai Rehabilitation Hospital in Connecticut thoroughly characterized upper arm and hand functions in MS patients, finding that disease duration and disability level differently affected various…
Research from Indiana University School of Medicine showed that D3T – a compound that triggers copying of antioxidant genes and production of the antioxidant glutathione – delays disease development and lowers disease severity in experimental autoimmune encephalomyelitis (EAE) animal models. The models mimicked multiple sclerosis (MS) in humans, advancing further exploration…
#CMSC16 – Fingolimod (Gilenya) Offers Consistent Health Benefits in Relapsing-Remitting MS Patients
Researchers at the Swedish Neuroscience Institute in Washington and Novartis Pharma revealed that Gilenya (fingolimod) induced a consistent and significant reduction in disease activity in patients with relapsing-remitting multiple sclerosis (RRMS). The results were recently presented at the June 1-4 Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual…
MS does not remit and the out dated term causes many people to delay taking medication, says Dr Patricia Coyle, Founder and Director of Stony Brook’s MS Comprehensive Care Center. Dr. Patricia Coyle. Last week, at the CMSC Annual Meeting in Maryland, during a live-streamed presentation covered by Multiple Sclerosis News Today, she…
Genentech, a member of the Roche Group, was founded more than 35 years ago and has been focused on a variety of research fields, including cancer, immunology, neurodegenerative disorders, metabolic diseases, and infectious diseases. Genentech has been committed to discovering and developing new medicines for patients with major diseases of the nervous…
Results from a Phase 2 clinical trial showed that five-year clinical outcomes of patients with highly active relapsing-remitting multiple sclerosis (RRMS) are significantly improved when patients are treated with high-dose immunosuppressive therapy combined with autologous hematopoietic cell transplantation. The study, “Five-Year Outcomes of Halt-MS: High- Dose Immunosuppressive Therapy and Autologous Hematopoietic Cell…
#CMSC16 – Delayed-release Dimethyl Fumarate Benefits Newly Diagnosed MS Patients, According to Study
Newly diagnosed patients with relapsing-remitting multiple sclerosis (RRMS) show significant improvements when treated with delayed-release dimethyl fumarate (DMF), especially in terms of reduction in confirmed disability progression. The study, “Efficacy of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Multiple Sclerosis Using a Composite Measure of Disability,” was recently presented at the…
Melissa A. Colbeck, an investigator at the Occupational Therapy, Health Sciences Centre in Winnipeg, Canada, studied how different sensory processing approaches, cognition, and fatigue influence the quality of life of patients with multiple sclerosis (MS). The findings suggested that establishing a relationship between the three factors and quality of life…
#CMSC16 – MS Care Should Include Fatigue, Sleep Quality and Inattentiveness Assessment, Study Shows
Mayis Al Dughmi, of the Physical Therapy and Rehabilitation Science at the University of Kansas Medical Center, recently presented her findings on the relationship between fatigue, measured using the Neurological Fatigue Index (NFI-MS), and sleep quality and attentiveness in patients with multiple sclerosis (MS). The findings indicate that cognitive…
A study, recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting in National Harbor, Md., showed MS patients of African decent might better benefit from treatment with alemtuzumab (Lemtrada) compared to subcutaneous interferon beta-1a (Rebif) – with lower rates of relapses evident over five years…
Researchers at the University of Arizona studied the psychosocial symptoms felt by a group of female patients with multiple sclerosis (MS) from the southwestern United States, and found significant relationships between depression, fatigue, and cognitive decline — symptoms also related with poorer quality of life and reduced mental and…
Researchers who looked at manifestations of loneliness found that the burden of loneliness is much higher in multiple sclerosis (MS) patients when compared to healthy people. The study, “Loneliness in Multiple Sclerosis: Putative Antecedents and Manifestations,” was recently presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) June…
One of the highlights at the “Comprehensive Care in MS and Symptom Management” session of the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting, was an attempt to address the exclusion of patients with multiple sclerosis (MS) from the design and delivery of healthcare aimed at this…
Sexual dysfunction correlates with depression and bladder dysfunction in Hispanic patients with multiple sclerosis (MS), according to the results of a recent study presented at the 2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). The study, “Sexual Dysfunction and Its Correlation to Depression and Bladder Dysfunction in…
Identifying multiple sclerosis (MS) patients who suffer from dysphagia — swallowing difficulties — early on allows the prevention of aspiration pneumonia, a leading cause of death in MS. Researchers at Baylor College of Medicine in Texas developed a screening tool to detect dysphagia and presented encouraging preliminary data on…
People with primary progressive multiple sclerosis (PPMS) are usually older and more disabled than those with relapsing-remitting MS, researchers at Washington University reported. The team is studying demographic and clinical characteristics of PPMS patients enrolled in the NARCOMS registry, to better understand their unmet needs and possibly improve research into potential treatments. The study, “…
Researchers at Johns Hopkins University in Baltimore found that visual function in multiple sclerosis (MS) patients correlates with cognitive function ands suggests that disease severity and outcomes of neuroprotective therapies in MS patients may be assessed through visual function measurements. The findings were recently presented in the oral presentation “…
The use of induced pluripotent stem cells to create disease-specific neurons and oligodendrocytes for the study of multiple sclerosis (MS) is hampered by the huge variability of features such cells possess. To get around this problem, researchers from Ohio State University created an atlas of how cell characteristics are linked…
Exercise might improve sleep quality in people with multiple sclerosis (MS), according to a study presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 annual meeting, June 1 – 4, at the Gaylord National Resort and Convention Center in National Harbor, Md. The study, “The Impact of…
While most multiple sclerosis (MS) researchers focus on the autoimmune and inflammatory processes of the disease, researchers at the Mind Research Network (MRN) believe that improving axonal function might contribute to better MS outcomes. Using Ampyra (dalfampridine), they thoroughly analyzed the function of nerve axon connections between the two brain…
Treadmill walking exercise training is beneficial for multiple sclerosis (MS) patients, increasing not only their cardiorespiratory fitness, but also their cognitive processing speed, according to the study “Systematically Developed Pilot Randomized Controlled Trial of Exercise and Cognition in Persons with Multiple Sclerosis,” recently presented at the Consortium of Multiple…
Biogen, announced that TYSABRI, a drug developed to treat people with multiple sclerosis (MS) has received a positive opinion from the European Medicine Agency (EMA) recommending its approval to be used in people with elapsing-remitting multiple sclerosis (RRMS).
Dr. Fred Lublin, a renowned multiple sclerosis (MS) expert at Mount Sinai Medical Center, helped launch the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting, June 1 – 4, in National Harbor, Md. with the John F. Kurtzke Memorial Lecture he titled “Do Relapses Really Matter?” “How relapses influence disease worsening,…
MS Research Australia Supporting Effort to Harness Anti-inflammatory Potential of Parasitic Worms
Researchers at the University of Technology Sydney (UTS) ithree institute are taking a novel approach in an attempt to halt disease progression in multiple sclerosis (MS). The scientists are planning to explore the anti-inflammatory potential of a controlled infection by parasitic worms as a way of preventing the harmful over-inflammation observed in MS and…
Researchers detected the expression of the gene ANKRD55 in immune cells, a gene that has been previously linked to multiple sclerosis (MS) in mice models of the disease. The results suggest a potential role of ANKRD55 in MS pathogenesis. The study, “Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55,”…
How would you feel about following a calorie-restricted diet, if it might reverse the symptoms of multiple sclerosis and help repair the damage caused by the disease? Scientists are so excited about the findings achieved so far that they are moving to large-scale human trials, and have already taken the unusual…
#CMSC16 — Multiple Sclerosis News Today to Provide Extensive On-Site Coverage of Annual Meeting
Multiple Sclerosis News Today will provide extended on-site coverage of the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting June 1-4 at the Gaylord National Resort and Convention Center in National Harbor, Maryland, across the harbor from the nation’s capital. Our news team will be posting feature articles on presentations…